Preparing to treat prions

Reviews in Medical Virology

Volumn 12, Issue 1, 2002, Pages 1-3

  Griffiths, P D ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; ENFUVIRTIDE; MEPACRINE; PEPTIDE; POLYAMINE; SURAMIN; T 1269; UNCLASSIFIED DRUG;

ALLELE; BRAIN SPONGIOSIS; CREUTZFELDT JAKOB DISEASE; DENDRITIC CELL; DRUG ACTIVITY; EDITORIAL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INOCULATION; KNOCKOUT GENE; NONHUMAN; PATHOGENESIS; PRION DISEASE; PROTEIN FOLDING; SCRAPIE AGENT; VIRUS TRANSMISSION;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PRION DISEASES; PRIONS;

EID: 0036148226     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.343     Document Type: Editorial

References (28)

1. Shattuck lecture-neurodegenerative diseases and prions
2. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies
3. Spontaneous neurodegeneration in transgenic mice with mutant prion protein
4. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity
5. Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system
6. PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain
7. PrP expression in B lymphocytes is not required for prion neuroinvasion
8. A crucial role for B cells in neuroinvasive scrapie
9. Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie
10. Pathogenesis of mouse scrapie: Patterns of agent replication in different parts of the CNS following intraperitoneal infection
11. A role for complement in transmissible spongiform encephalopathies
12. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves
13. Mimicking dominant negative inhibition of prion replication through structure-based drug design
14. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides
15. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
16. Branched polyamines cure prion-infected neuroblastoma cells
17. Intracellular re-routing of prion protein prevents propagation of PrP(Sc) and delays onset of prion disease
18. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity
19. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells
20. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie
21. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies
22. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures
23. Antiviral drugs with extra-cellular sites of action
24. Predicted vCJD mortality in Great Britain
25. Variant CJD epidemiology: Joining up the dots
26. Predictability of the UK Variant Creutzfeldt-Jakob Disease Epidemic
27. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation
28. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994-2000